Compare Altria Group Inc (MO) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Altria Group Inc vs Stryker Corporation — how do they compare? Altria Group Inc trades at $71.54 (market cap $119.25B), while Stryker Corporation trades at $277.34 (market cap $106.24B). The key difference: Altria Group Inc and Stryker Corporation are close in size by market cap, and Altria Group Inc pays the higher dividend (6.22%). Which is the better fit depends on your goals — on Pluang, investors hold Altria Group Inc for 154 Days and Stryker Corporation for 21 Days on average.
| MO | SYK | |
|---|---|---|
Market Cap | $119.25B | $106.24B |
Volume | 11,178,169 | 2,982,001 |
Sector | Consumer Staples | Health |
52-Week High | $74.92 | $388.35 |
52-Week Low | $54.72 | $269.75 |
Typical Hold Time | 154 Days | 21 Days |
Enterprise Value | $141.46B | $117.70B |
Dividend Yield | 6.22% | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Altria Group (MO) trades at $71.68, up 3.31% with a bullish technical signal supported by moving averages. The stock shows strong profitability with 72.24% gross margins and 39% net income margin, though revenue has declined from $20.7B in 2022 to $20.1B in 2025. Recent earnings show mixed results with one beat and two misses in the last four quarters. The company maintains a substantial dividend yield with 60 consecutive increases, supported by $9.3B in operating cash flow.
MO presents a high-yield opportunity with analyst consensus favoring Buy ratings (61.5%), but faces significant risks including negative shareholder equity, declining margins, and regulatory pressures. The stock trades below the $69.71 consensus price target, suggesting limited upside potential. Investors must weigh the attractive 6.6% dividend yield against fundamental challenges in the core tobacco business and balance sheet concerns.
Stryker (SYK) trades at $277.52, up 0.77% today, amid a mixed technical and fundamental backdrop. The stock shows a bearish technical signal with key support at $274 and resistance at $279. Fundamentally, the company reported strong profitability with a 14.43% net income margin in 2026 and beat EPS estimates in two of the last three quarters. However, recent news highlights potential legal and manufacturing issues that have pressured investor sentiment.
The outlook is cautiously optimistic, with a consensus price target of $368.11 implying significant upside. Investment opportunities lie in SYK's robust earnings growth and market leadership in medical technology, but risks include ongoing legal investigations and persistent manufacturing challenges that could impact future performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
